<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ravulizumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ravulizumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ravulizumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="120006" href="/d/html/120006.html" rel="external">see "Ravulizumab: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="127141" href="/d/html/127141.html" rel="external">see "Ravulizumab: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F52442175"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious meningococcal infection:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Life-threatening meningococcal infections/sepsis have occurred in patients treated with ravulizumab. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.</p>
<p style="text-indent:-2em;margin-left:2em;">Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.</p>
<p style="text-indent:-2em;margin-left:2em;">Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of ravulizumab, unless the risks of delaying ravulizumab therapy outweigh the risk of developing a meningococcal infection.</p>
<p style="text-indent:-2em;margin-left:2em;">Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the risk of meningococcal infections, ravulizumab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called Ultomiris REMS.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52457342"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ultomiris</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56253394"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ultomiris</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F52442180"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Complement C5 Inhibitor;</li>
<li>
                        Complement Inhibitor;</li>
<li>
                        Monoclonal Antibody;</li>
<li>
                        Monoclonal Antibody, Complement Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F52464599"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Vaccinate with meningococcal vaccine at least 2 weeks prior to treatment initiation; revaccinate according to current guidelines. If urgent ravulizumab initiation is necessary and less than 2 weeks after vaccination, provide 2 weeks of antibacterial prophylaxis. In unvaccinated patients, administer meningococcal vaccine as soon as possible and provide 2 weeks of antibacterial prophylaxis. To reduce the risk for meningococcal disease, consider antimicrobial prophylaxis with oral antibiotics (penicillin, or macrolides if penicillin-allergic) for the duration of ravulizumab therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28704351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28704351'])">Ref</a></span>). Following the first maintenance dose, the ravulizumab dosing schedule is allowed to occasionally vary within 1 day (SUBQ) or 7 days (IV) of the scheduled infusion day, although the subsequent dose should be administered according to the original schedule.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fbfde62-92ad-44b8-a4cb-302a8c890eef">Atypical hemolytic uremic syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atypical hemolytic uremic syndrome: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>A minimum treatment duration of 6 months is recommended. Dose is based on weight at time of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight 20 kg to &lt;30 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>900 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>2,100 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight 30 kg to &lt;40 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>
<b></b>1,200 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>2,700 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight 40 kg to &lt;60 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>2,400 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>
<b></b>3,000 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight 60 kg to &lt;100 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>2,700 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>
<b></b>3,300 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight ≥100 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>3,000 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>
<b></b>3,600 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b>
<i> Weight ≥40 kg: </i>Maintenance dose: 490 mg once weekly starting 2 weeks after weight-based IV loading dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb166acb-5b02-4fdb-9b10-9ee28a0e5978">Myasthenia gravis, generalized, chronic immunosuppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis, generalized, chronic immunosuppression:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dose is based on weight at time of treatment. Use in patients with anti-acetylcholine receptor antibody-positive (AChR+) myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight 40 kg to &lt;60 kg:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>IV: </b>2,400 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>IV: </b>3,000 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight 60 kg to &lt;100 kg:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>IV: </b>2,700 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>IV: </b>3,300 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight ≥100 kg:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>IV: </b>3,000 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>IV: </b>3,600 mg once every 8 weeks starting 2 weeks after the loading dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="533b3d0e-6a18-4264-be77-ae9e03c9578d">Neuromyelitis optica spectrum disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromyelitis optica spectrum disorder (Canadian labeling only):</b> Dose is based on weight at time of treatment:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight 40 kg to &lt;60 kg:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>IV: </b>2,400 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>IV: </b>3,000 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight 60 kg to &lt;100 kg:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>IV: </b>2,700 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>IV: </b>3,300 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight ≥100 kg:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>IV: </b>3,000 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>IV: </b>3,600 mg once every 8 weeks starting 2 weeks after the loading dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="baae2201-4105-4717-bf6e-c5c875d26f7c">Paroxysmal nocturnal hemoglobinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paroxysmal nocturnal hemoglobinuria:</b> Dose is based on weight at time of treatment:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight 20 kg to &lt;30 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>
<b></b>900 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>
<b></b>2,100 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight 30 kg to &lt;40 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>
<b></b>1,200 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>
<b></b>2,700 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight 40 kg to &lt;60 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>
<b></b>2,400 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>
<b></b>3,000 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight 60 kg to &lt;100 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>
<b></b>2,700 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>
<b></b>3,300 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight ≥100 kg:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>IV: </b>
<b></b>3,000 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV: </b>3,600 mg once every 8 weeks starting 2 weeks after the loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b>
<i> Weight ≥40 kg: </i>Maintenance dose: 490 mg once weekly starting 2 weeks after weight-based IV loading dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from eculizumab to IV ravulizumab:</b> When converting from eculizumab to IV ravulizumab, administer the ravulizumab loading dose at the time of the next scheduled eculizumab dose and then administer ravulizumab maintenance doses once every 4 or 8 weeks (depending on body weight) beginning 2 weeks after the ravulizumab loading dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from eculizumab to SUBQ ravulizumab:</b> When converting from eculizumab to SUBQ ravulizumab, administer IV ravulizumab as the loading dose at the time of the next scheduled eculizumab dose and then administer SUBQ ravulizumab maintenance doses weekly beginning 2 weeks after the ravulizumab IV loading dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from ravulizumab IV to SUBQ:</b> When converting from IV ravulizumab to SUBQ ravulizumab, begin SUBQ maintenance dose 8 weeks after last IV maintenance dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from ravulizumab SUBQ to IV:</b> When converting from SUBQ ravulizumab to IV ravulizumab, begin IV maintenance dose 1 week after last SUBQ maintenance dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Supplemental dose following plasma exchange, plasmapheresis, or IV immune globulin (IVIG):</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Supplemental Ravulizumab Doses Following PE, PP, or IVIG<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">Weight (kg)<sup>b</sup></p></th>
<th align="left">
<p style="text-indent:0em;">Most recent ravulizumab dose (mg)</p></th>
<th align="left">
<p style="text-indent:0em;">Supplemental ravulizumab dose (mg) following each PE or PP intervention</p></th>
<th align="left">
<p style="text-indent:0em;">Supplemental ravulizumab dose (mg) following completion of an IVIG cycle</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a</sup> PE = plasma exchange; PP = plasmapheresis; IVIG = IV immune globulin.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<b>
<sup>b </sup></b>Weight at time of treatment.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">40 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,400 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,200 mg</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">600 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">60 to &lt;100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,700 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">600 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,300 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,800 mg</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">≥100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">600 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,800 mg</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">Timing of ravulizumab supplemental dose</p></td>
<td align="left">
<p style="text-indent:0em;">Within 4 hours following each PE or PP intervention</p></td>
<td align="left">
<p style="text-indent:0em;">Within 4 hours following completion of an IVIG cycle</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F52464601"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, renal impairment had no clinically important effect on ravulizumab pharmacokinetics.</p></div>
<div class="block doha drugH1Div" id="F52464602"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, hepatic impairment had no clinically important effect on ravulizumab pharmacokinetics.</p></div>
<div class="block dot drugH1Div" id="F52464603"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Adverse reaction during infusion: May slow or stop infusion (at discretion of health care provider). Interrupt infusion and begin appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.</p></div>
<div class="block doe drugH1Div" id="F52464600"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F54112570"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="127141" href="/d/html/127141.html" rel="external">see "Ravulizumab: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Vaccinate with meningococcal vaccine at least 2 weeks prior to treatment initiation; revaccinate according to current guidelines. If urgent ravulizumab initiation is necessary and it has been &lt;2 weeks after vaccination, provide 2 weeks of antibacterial prophylaxis. To reduce the risk for meningococcal disease, consider antimicrobial prophylaxis with oral antibiotics (penicillin, or macrolides if penicillin-allergic) for the duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28704351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28704351'])">Ref</a></span>). Multiple concentrations of solutions are available (10 mg/mL and 100 mg/mL); only a single concentration should be used to prepare a dose for infusion (see "Preparation for Administration").</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7d076957-a68a-4709-b7c0-92a772b784d4">Atypical hemolytic uremic syndrome or paroxysmal nocturnal hemoglobinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atypical hemolytic uremic syndrome (aHUS) or paroxysmal nocturnal hemoglobinuria (PNH): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV infusion: Administer the first maintenance dose 2 weeks after loading dose; for subsequent maintenance doses, the interval varies with weight; use precaution to ensure appropriate interval. Dose is based on weight at time of treatment for that dose. Following the first maintenance dose, the ravulizumab dosing schedule is allowed to occasionally vary within 7 days of the scheduled infusion day; subsequent dose should be administered according to the original schedule. For aHUS, treatment should continue for a minimum of 6 months.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Weight</p>
<p style="text-indent:0em;">(at time of treatment)</p></th>
<th align="center">
<p style="text-indent:0em;">Loading Dose</p>
<p style="text-indent:0em;">(fixed, mg/dose)</p></th>
<th align="center">
<p style="text-indent:0em;">Maintenance Dose</p>
<p style="text-indent:0em;">(fixed, mg/dose)</p></th>
<th align="center">
<p style="text-indent:0em;">Maintenance Interval</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">5 to &lt;10 kg</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 4 weeks</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;20 kg</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20 to &lt;30 kg</p></td>
<td align="center">
<p style="text-indent:0em;">900 mg</p></td>
<td align="center">
<p style="text-indent:0em;">2,100 mg</p></td>
<td align="center" rowspan="5">
<p style="text-indent:0em;">Every 8 weeks</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to &lt;40 kg</p></td>
<td align="center">
<p style="text-indent:0em;">1,200 mg</p></td>
<td align="center">
<p style="text-indent:0em;">2,700 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">40 to &lt;60 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2,400 mg</p></td>
<td align="center">
<p style="text-indent:0em;">3,000 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60 to &lt;100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">2,700 mg</p></td>
<td align="center">
<p style="text-indent:0em;">3,300 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3,000 mg</p></td>
<td align="center">
<p style="text-indent:0em;">3,600 mg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosing adjustment for toxicity:</i> May slow or stop infusion at the discretion of the health care provider if adverse reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion from eculizumab:</i> When converting from eculizumab to ravulizumab, administer the ravulizumab loading dose 2 weeks after the last eculizumab dose and then administer subsequent ravulizumab maintenance doses according to weight-based schedule, beginning 2 weeks after the ravulizumab loading dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F54112600"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, renal impairment had no clinically important effect on ravulizumab pharmacokinetics.</p></div>
<div class="block dohp drugH1Div" id="F54112601"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, hepatic impairment had no clinically important effect on ravulizumab pharmacokinetics.</p></div>
<div class="block adr drugH1Div" id="F52447537"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults with paroxysmal nocturnal hemoglobinuria (PNH) unless otherwise indicated for generalized myasthenia gravis (gMG).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (gMG: 15%; PNH: 4% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (SUBQ: 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (9% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (gMG, PNH: 8% to 39%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (gMG, PNH: 6%), nausea (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (gMG: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (1%; including hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (gMG: 9%; PNH: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (5%), back pain (gMG: 8%), limb pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Meningococcal infection, sepsis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Hyperthermia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F52442178"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Unresolved <i>Neisseria meningitidis</i> infection; patients not currently vaccinated against <i>N. meningitidis</i>, unless the risks of delaying ravulizumab treatment outweigh the risks of developing a meningococcal infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to ravulizumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F52464587"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Ravulizumab blocks terminal complement activation and therefore may increase the risk for susceptibility to bacterial infections, especially encapsulated bacteria, such as infections caused by <i>Neisseria meningitidis </i>but also <i>Streptococcus pneumoniae, Haemophilus influenzae, </i>and, to a lesser extent, <i>Neisseria gonorrhoeae. </i>Pediatric patients receiving ravulizumab may be at increased risk for serious <i>S. pneumoniae</i> and <i>H. influenzae</i> type b (Hib) infections; vaccinate for <i>S. pneumoniae</i> and Hib according to the Advisory Committee on Immunization Practices (ACIP) recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Administration of ravulizumab may result in infusion reactions, including anaphylaxis and hypersensitivity. In clinical trials, a small number of patients experienced infusion reactions (lower back pain, BP changes, and limb discomfort) during administration. Infusion reactions did not require ravulizumab discontinuation. If signs of cardiovascular instability or respiratory compromise occur, interrupt infusion and manage supportively.</p>
<p style="text-indent:-2em;margin-left:4em;">• Meningococcal infection: The use of ravulizumab increases susceptibility to serious meningococcal infections (septicemia and/or meningitis). Meningococcal disease due to any serogroup may occur. If urgent ravulizumab therapy is indicated in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide at least 2 weeks of antibacterial prophylaxis. To reduce the risk for meningococcal disease, consider antimicrobial prophylaxis with oral antibiotics (penicillin, or macrolides if penicillin-allergic) for the duration of ravulizumab therapy (McNamara 2017). A small number of vaccinated patients developed serious meningococcal infections/sepsis while receiving ravulizumab treatment in studies; the patients recovered while continuing ravulizumab treatment. Educate patients on signs/symptoms of meningitis and steps necessary to seek immediate medical care. Consider ravulizumab discontinuation in patients who are undergoing treatment for serious meningococcal infection. Revaccinate for meningococcal disease according to ACIP recommendations, taking the duration of ravulizumab therapy into consideration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulation: Treatment with ravulizumab should not alter anticoagulation management; the effect of anticoagulant therapy withdrawal is unknown.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Acrylic adhesive: On-body injector uses acrylic adhesive; allergic reactions may occur in patients with an allergy to acrylic adhesive. Consider premedication and supportive therapy if allergic reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Vials are intended for IV use only. Prefilled cartridge and on-body injector are intended for SUBQ maintenance use only.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation in atypical hemolytic uremic syndrome: If thrombotic microangiopathy complications occur after discontinuation, consider restarting ravulizumab treatment or appropriate organ-specific supportive measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation in paroxysmal nocturnal hemoglobinuria: If hemolysis signs/symptoms (including elevated lactate dehydrogenase) occur after discontinuation, consider restarting ravulizumab treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Plasmapheresis/plasma exchange: Plasmapheresis and plasma exchange may reduce ravulizumab levels; supplemental ravulizumab doses are recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program:<b>
<b></b></b>Counsel patients about the risk of meningococcal infection/sepsis; provide REMS educational materials to patients, and ensure patients are vaccinated with meningococcal vaccines. Additional information is available at www.ultomirisrems.com or 1-888-765-4747.</p></div>
<div class="block prod-avail drugH1Div" id="F57055829"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Ultomiris 245 mg/3.5 mL single-dose prefilled cartridge: FDA approved July 2022; anticipated availability currently unknown.</p></div>
<div class="block foc drugH1Div" id="F52457343"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ultomiris: Ravulizumab-cwvz 300 mg/3 mL (3 mL); Ravulizumab-cwvz 300 mg/30 mL (30 mL [DSC]); Ravulizumab-cwvz 1100 mg/11 mL (11 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F52457341"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52605670"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ultomiris Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/3 mL (per mL): $2,561.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1100MG/11ML (per mL): $2,561.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56253395"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ultomiris: 300 mg/30 mL (30 mL); Ravulizumab-cwvz 300 mg/3 mL (3 mL); Ravulizumab-cwvz 1100 mg/11 mL (11 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F52464608"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse through a 0.2- or 0.22-micron filter. Allow solution to adjust to room temperature (do not use a heat source) prior to infusion. Infusion rate for loading, maintenance, and supplemental doses is based on patient weight.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>3 mL </b>
<b>or 11 mL vial (100 mg/mL):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Loading dose:</b></i></p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Loading Dose</b> Infusion Recommendations Using <i>
<b>100 mg/mL (3 mL and 11 mL)</b></i> Vials</caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Weight (kg)<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Loading dose (mg)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Total volume to be administered (mL)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Minimum infusion time (hours)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Maximum infusion rate (mL/hour)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Weight at time of treatment.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 to &lt;30 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">900 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 to &lt;40 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,200 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">24 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,400 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 to &lt;100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,700 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">90 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">150 mL/hour</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Maintenance dose:</b></i></p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Maintenance Dose </b>Infusion Recommendations Using <i>
<b>100 mg/mL (3 mL and 11 mL) </b></i>Vials</caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Weight (kg)<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Maintenance dose (mg)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Total volume to be administered (mL)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Minimum infusion time (hours)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Maximum infusion rate (mL/hour)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Weight at time of treatment.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 to &lt;30 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,100 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">42 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.3 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">33 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 to &lt;40 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,700 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.1 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">67 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 to &lt;100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,300 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">66 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">95 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">72 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">144 mL/hour</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Supplemental dose:</b></i></p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Supplemental Dose </b>Infusion Recommendations Using<i>
<b> 100 mg/mL (3 mL and 11 mL) </b></i>Vials<sup>a</sup></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Weight (kg)<sup>b</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Supplemental dose (mg)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Total volume to be administered (mL)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Minimum infusion time (hours)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Maximum infusion rate (mL/hour)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Supplemental doses are only indicated following plasma exchange, plasmapheresis, or IV immune globulin (IVIG) therapy.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Weight at time of treatment.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">40 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.25 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,200 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">24 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.42 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">57 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 mL/hour</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">60 to &lt;100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.36 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">83 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,800 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">36 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.42 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86 mL/hour</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">≥100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.17 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">71 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.25 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,800 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">36 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.28 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">129 mL/hour</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>30 mL vial (10 mg/mL):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Loading dose:</b></i></p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Loading Dose</b> Infusion Recommendations Using <i>10 mg/mL (30 mL)</i> Vials</caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Weight (kg)<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Loading dose (mg)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Total volume to be administered (mL)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Minimum infusion time (hours)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Maximum infusion rate (mL/hour)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Weight at time of treatment.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 to &lt;30 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">900 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">180 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 to &lt;40 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,200 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.3 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">185 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,400 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">480 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.9 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">253 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 to &lt;100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,700 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">540 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.7 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">318 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.8 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">334 mL/hour</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Maintenance dose:</b></i></p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Maintenance Dose </b>Infusion Recommendations Using <i>
<b>10 mg/mL (30 mL) </b></i>Vials</caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Weight (kg)<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Maintenance dose (mg)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Total volume to be administered (mL)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Minimum infusion time (hours)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Maximum infusion rate (mL/hour)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Weight at time of treatment.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 to &lt;30 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,100 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3.3 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">128 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 to &lt;40 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,700 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">540 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.8 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">193 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.3 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">261 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 to &lt;100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,300 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">660 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">330 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">720 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.2 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">328 mL/hour</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Supplemental dose:</b></i></p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Supplemental Dose </b>Infusion Recommendations Using<i>
<b> 10 mg/mL (30 mL) </b></i>Vials<sup>a</sup></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Weight (kg)<sup>b</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Supplemental dose (mg)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Total volume to be administered (mL)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Minimum infusion time (hours)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Maximum infusion rate (mL/hour)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Supplemental doses are only indicated following plasma exchange, plasmapheresis, or IV immune globulin (IVIG) therapy.</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Weight at time of treatment.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">40 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,200 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 hour</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.2 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">250 mL/hour</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">60 to &lt;100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 hour</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,800 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">360 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.1 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">327 mL/hour</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">≥100 kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 hour</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mL/hour</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,800 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">360 mL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.1 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">327 mL/hour</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Assess immunization status prior to initiation; patients should receive meningococcal vaccine at least 2 weeks prior to treatment initiation. If ravulizumab must be initiated urgently and less than 2 weeks after vaccination, provide 2 weeks of antibacterial prophylaxis; in unvaccinated patients, administer meningococcal vaccine as soon as possible and provide 2 weeks of antibacterial prophylaxis. Revaccinate according to current guidelines.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>SUBQ:</b> For use with the on-body delivery system; see manufacturer's labeling for detailed administration instructions. Self-administration may occur after proper training from a health care provider. Administer SUBQ into abdomen, thigh, or upper arm; do not administer into tender, bruised, red, or hard skin; avoid injecting into areas with scars, stretch marks, wrinkles, skin folds, tattoos, moles, or excessive hair. Rotate injection sites. The 2 on-body delivery systems may be administered concurrently or sequentially; each injection is administered over ~10 minutes.</p></div>
<div class="block admp drugH1Div" id="F54112609"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Assess immunization status prior to initiation (see "Dosing: Pediatric" for specific information).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infuse through a 0.2 or 0.22 micron filter. If previous refrigeration, allow solution to adjust to room temperature at ambient air temperature (do not use a heat source) prior to infusion. Infusion rate for loading and maintenance dose is highly variable as it is based on concentration of ravulizumab used to prepare the infusion and patient weight; use extra precaution. Decrease infusion rate or discontinue for infusion reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Multiple final concentrations for infusion exist (5 mg/mL and 50 mg/mL) and each concentration has different infusion rates; use extra precaution verifying concentration of infusion solution.</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="5">
<p style="text-indent:0em;">
<b>5 mg/mL Solution Administration Rates and Infusion Times </b></p>
<p style="text-indent:0em;">Final Concentration of Infusion <i>
<b>5 mg/mL</b></i>
<b>
<sup>a</sup></b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Dose type</p></th>
<th align="center">
<p style="text-indent:0em;">Total dose/Total volume</p>
<p style="text-indent:0em;">
<b>(5 mg/mL)</b></p></th>
<th align="center">
<p style="text-indent:0em;">Maximum infusion rate</p>
<p style="text-indent:0em;">(mL/hour)</p></th>
<th align="center">
<p style="text-indent:0em;">Minimum infusion time</p>
<p style="text-indent:0em;">(hours)</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Solutions prepared from the 10 mg/mL (30 mL) vial and further diluted in NS.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">5 to &lt;10 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg/120 mL</p></td>
<td align="center">
<p style="text-indent:0em;">31 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">3.8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg/60 mL</p></td>
<td align="center">
<p style="text-indent:0em;">31 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.9 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">10 to &lt;20 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg/120 mL</p></td>
<td align="center">
<p style="text-indent:0em;">63 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.9 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg/120 mL</p></td>
<td align="center">
<p style="text-indent:0em;">63 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.9 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">20 to &lt;30 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">900 mg/180 mL</p></td>
<td align="center">
<p style="text-indent:0em;">120 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.5 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">2,100 mg/420 mL</p></td>
<td align="center">
<p style="text-indent:0em;">127 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">3.3 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">30 to &lt;40 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">1,200 mg/240 mL</p></td>
<td align="center">
<p style="text-indent:0em;">184 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.3 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">2,700 mg/540 mL</p></td>
<td align="center">
<p style="text-indent:0em;">192 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">2.8 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">40 to &lt;60 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">2,400 mg/480 mL</p></td>
<td align="center">
<p style="text-indent:0em;">252 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.9 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">3,000 mg/600 mL</p></td>
<td align="center">
<p style="text-indent:0em;">257 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">2.3 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">60 to &lt;100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">2,700 mg/540 mL</p></td>
<td align="center">
<p style="text-indent:0em;">317 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.7 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">3,300 mg/660 mL</p></td>
<td align="center">
<p style="text-indent:0em;">330 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">2 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">≥100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">3,000 mg/600 mL</p></td>
<td align="center">
<p style="text-indent:0em;">333 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">3,600 mg/720 mL</p></td>
<td align="center">
<p style="text-indent:0em;">327 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">2.2 hours</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="5">
<p style="text-indent:0em;">
<b>50 mg/mL Solution Administration Rates and Infusion Times </b></p>
<p style="text-indent:0em;">Final Concentration of Infusion<i>
<b> 50 mg/mL</b></i>
<b>
<sup>a</sup></b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Dose type</p></th>
<th align="center">
<p style="text-indent:0em;">Total dose/Total volume</p>
<p style="text-indent:0em;">
<b>(50 mg/mL)</b></p></th>
<th align="center">
<p style="text-indent:0em;">Maximum infusion rate</p>
<p style="text-indent:0em;">(mL/hour)</p></th>
<th align="center">
<p style="text-indent:0em;">Minimum infusion time</p>
<p style="text-indent:0em;">(hours)</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Solutions prepared from the 100 mg/mL (3 mL or 11 mL) vial and further diluted in NS.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">5 to &lt;10 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg/12 mL</p></td>
<td align="center">
<p style="text-indent:0em;">8 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.4 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg/6 mL</p></td>
<td align="center">
<p style="text-indent:0em;">8 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">10 to &lt;20 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg/12 mL</p></td>
<td align="center">
<p style="text-indent:0em;">16 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg/12 mL</p></td>
<td align="center">
<p style="text-indent:0em;">16 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">20 to &lt;30 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">900 mg/18 mL</p></td>
<td align="center">
<p style="text-indent:0em;">30 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.6 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">2,100 mg/42 mL</p></td>
<td align="center">
<p style="text-indent:0em;">33 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.3 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">30 to &lt;40 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">1,200 mg/24 mL</p></td>
<td align="center">
<p style="text-indent:0em;">46 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.5 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">2,700 mg/54 mL</p></td>
<td align="center">
<p style="text-indent:0em;">49 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">1.1 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">40 to &lt;60 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">2,400 mg/48 mL</p></td>
<td align="center">
<p style="text-indent:0em;">64 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">3,000 mg/60 mL</p></td>
<td align="center">
<p style="text-indent:0em;">65 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.9 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">60 to &lt;100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">2,700 mg/54 mL</p></td>
<td align="center">
<p style="text-indent:0em;">92 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.6 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">3,300 mg/66 mL</p></td>
<td align="center">
<p style="text-indent:0em;">99 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.7 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">≥100 kg</p></td>
<td align="center">
<p style="text-indent:0em;">Loading</p></td>
<td align="center">
<p style="text-indent:0em;">3,000 mg/60 mL</p></td>
<td align="center">
<p style="text-indent:0em;">144 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.4 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;">3,600 mg/72 mL</p></td>
<td align="center">
<p style="text-indent:0em;">144 mL/hour</p></td>
<td align="center">
<p style="text-indent:0em;">0.5 hours</p></td></tr></tbody></table></div>
<div class="block meg drugH1Div" id="F53797884"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Ultomiris: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F761108s023lbl.pdf%23page%3D41&amp;token=%2F%2FlYGzkjbdA6qugV1v1mzK2WSTzYvIv6G2HI0kEClTZAmdSMssumQqWLy78IYO3zJ0lbslPQk09jjiFSV0bFWqkm7x6zs0qHze5ML91ohIHOuT9dd35L4Blv46ZQFabC&amp;TOPIC_ID=119990" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761108s023lbl.pdf#page=41</a></p></div>
<div class="block use drugH1Div" id="F52442182"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atypical hemolytic uremic syndrome:</b> Treatment of atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy in adult and pediatric patients ≥1 month of age.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not indicated for the treatment of Shiga toxin <i>Escherichia coli-</i>related hemolytic uremic syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis, generalized, chronic immunosuppression (IV only):</b> Treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody-positive (AChR+).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromyelitis optica spectrum disorder (Canadian labeling only):</b> Treatment of adults with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Paroxysmal nocturnal hemoglobinuria:</b> Treatment of paroxysmal nocturnal hemoglobinuria in adults and pediatric patients ≥1 month of age.</p></div>
<div class="block mst drugH1Div" id="F52464579"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ravulizumab may be confused with eculizumab, ramucirumab, ranibizumab, raxibacumab, reslizumab.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F52457465"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F52457462"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: May decrease the serum concentration of Ravulizumab. Management: Administer a supplemental dose of ravulizumab (600 mg) within 4 hours of completion of the immune globulin cycle.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F52464581"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ravulizumab is a humanized monoclonal antibody (IgG<sub>2</sub>). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Data related to maternal use of ravulizumab during pregnancy (Tomazos 2020) or immediately postpartum (Gäckler 2021) are limited.</p>
<p style="text-indent:0em;margin-top:2em;">Adverse pregnancy outcomes are associated with untreated paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Adverse maternal outcomes associated with PNH may include worsening cytopenias, thrombotic events, infections, bleeding, fetal loss, and increased maternal mortality; increased fetal death and premature delivery is also reported. Patients with aHUS may have an increased risk of preeclampsia and preterm delivery; intrauterine growth restriction/low birth weight and fetal death may also occur.</p></div>
<div class="block brc drugH1Div" id="F52464582"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ravulizumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 8 months after the last ravulizumab dose.</p></div>
<div class="block mop drugH1Div" id="F52464611"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Assess immunization status (prior to treatment). Monitor for early signs of meningococcal infection; evaluate immediately if infection is suspected. Monitor closely for signs/symptoms of worsening infection (if administering ravulizumab to patients with active systemic infections). Monitor for signs/symptoms of an infusion reaction; monitor patients receiving SUBQ injection for at least 1 hour after completion of injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>After ravulizumab discontinuation for paroxysmal nocturnal hemoglobinuria:</i> Monitor closely for ≥16 weeks (after discontinuation) to detect hemolysis and other reactions; monitor for signs/symptoms of hemolysis (eg, elevated lactate dehydrogenase [LDH] along with sudden decrease in paroxysmal nocturnal hemoglobinuria clone size or hemoglobin, or re-appearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, shortness of breath [dyspnea], major adverse vascular event [including thrombosis], dysphagia, or erectile dysfunction) after discontinuation of ravulizumab treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>After ravulizumab discontinuation for atypical hemolytic uremic syndrome</i>: Monitor closely for ≥12 months (after discontinuation) for signs/symptoms of thrombotic microangiopathy (TMA) complications. TMA complications may be identified by clinical symptoms (changes in mental status, seizures, angina, dyspnea, thrombosis, or increasing blood pressure) in addition to ≥2 of the following laboratory values observed concurrently (and confirmed by a second measurement 28 days apart with no interruption): platelet count decreased ≥25% compared to baseline or peak count during ravulizumab treatment; serum creatinine increased ≥25% compared to baseline or to nadir during ravulizumab treatment; or LDH increased ≥25% compared to baseline or to nadir during ravulizumab treatment.</p></div>
<div class="block pha drugH1Div" id="F52464592"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ravulizumab is a humanized monoclonal antibody which is a terminal complement inhibitor that specifically binds to the complement protein C5 (with high affinity), inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing generation of the terminal complement complex C5b9. Ravulizumab inhibits terminal complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated thrombotic microangiopathy in atypical hemolytic uremic syndrome. The C5 inhibition of complement-mediated hemolysis achieved by ravulizumab in patients with PNH is immediate, thorough, and sustained (Lee 2019). The mechanism in generalized myasthenia gravis has not been fully elucidated but is presumed to involve reduction of terminal complement complex C5b-9 at the neuromuscular junction.</p></div>
<div class="block phk drugH1Div" id="F52464593"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Lactate dehydrogenase (LDH) reduction: Rapid and sustained, beginning as early as day 8 (Roth 2018). LDH normalization: By week 4 (in complement-inhibitor naive patients with paroxysmal nocturnal hemoglobinuria [PNH]).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: ~79%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV: 5.22 L (atypical hemolytic uremic syndrome [aHUS] patients); 5.3 L (PNH patients); 5.74 L (generalized myasthenia gravis patients [gMG]); SUBQ: 5.3 L (PNH patients).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: IV: 51.8 days (aHUS patients); 49.6 days (PNH patients); 56.6 days (gMG patients); SUBQ: 52.4 days (PNH patients).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: IV: 0.08 L/day; SUBQ: 0.07 L/day.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56521784"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ultomiris</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33407224">
<a name="33407224"></a>Gäckler A, Schönermarck U, Dobronravov V, et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. <i>BMC Nephrol</i>. 2021;22(1):5. doi:10.1186/s12882-020-02190-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/33407224/pubmed" id="33407224" target="_blank">33407224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30510080">
<a name="30510080"></a>Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. <i>Blood</i>. 2019;133(6):530-539. doi:10.1182/blood-2018-09-876136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/30510080/pubmed" id="30510080" target="_blank">30510080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28704351">
<a name="28704351"></a>McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(27):734-737. doi:10.15585/mmwr.mm6627e1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/28704351/pubmed" id="28704351" target="_blank">28704351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30171081">
<a name="30171081"></a>Röth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. <i>Blood Adv</i>. 2018;2(17):2176-2185. doi:10.1182/bloodadvances.2018020644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/30171081/pubmed" id="30171081" target="_blank">30171081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tomazos I, Sierra JR, Johnston KM, Cheung A, Brodsky RA, Weitz IC. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. <i>Hematology</i>. 2020;25(1):327-334. doi:10.1080/16078454.2020.1807226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ravulizumab-drug-information/abstract-text/32856539/pubmed" id="32856539" target="_blank">32856539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ultomiris.1">
<a name="Ultomiris.1"></a>Ultomiris (ravulizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ultomiris.2">
<a name="Ultomiris.2"></a>Ultomiris (ravulizumab) [product monograph]. Bear, Switzerland: Alexion Pharma GmbH; October 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 119990 Version 125.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
